Protein C Test for Thrombophilia Diagnosis at Chughtai Lab

Protein C Test at Chughtai Lab

The Protein C test is a highly specialized hematological assay designed to measure the activity or concentration of Protein C in the blood. Protein C is a vital, vitamin K-dependent glycoprotein synthesized by the liver that plays a central role in the body’s natural anticoagulant system. Under normal physiological conditions, when the coagulation cascade is activated to prevent bleeding, Protein C is converted into its active form, Activated Protein C (APC), by the thrombin-thrombomodulin complex on the endothelial cell surface. APC, along with its cofactor Protein S, enzymatically cleaves and inactivates clotting factors Va and VIIIa. This inactivation acts as a critical biochemical brake, limiting further thrombin generation and preventing excessive, uncontrolled blood clot formation within the vascular system. When a patient has a deficiency or dysfunction of Protein C, this regulatory mechanism fails, leading to an increased risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE).

At Chughtai Lab, Pakistan’s premier diagnostic institution, the Protein C test is performed using advanced automated coagulation analyzers that utilize state-of-the-art chromogenic or clot-based functional assays. This test is of paramount clinical importance for evaluating patients suspected of having inherited or acquired thrombophilia. Inherited Protein C deficiency is an autosomal dominant disorder that can present as a mild heterozygous state with recurrent venous thrombosis, or as a catastrophic homozygous state in newborns, known as neonatal purpura fulminans. Acquired deficiencies are much more common and can occur due to severe liver disease, vitamin K deficiency, disseminated intravascular coagulation (DIC), active thrombosis, or the use of oral anticoagulant therapies such as warfarin. By accurately quantifying Protein C activity, clinicians can make informed decisions regarding the duration and intensity of anticoagulant therapy, assess familial risk, and implement preventive measures during high-risk clinical periods such as surgery, pregnancy, or prolonged immobilization.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is absolutely critical for obtaining accurate and clinically meaningful Protein C test results, as several external factors and medications can significantly alter the levels of this protein. Patients must adhere to the following preparation guidelines:

• Anticoagulant Medication Cessation: The most critical preparation step is the temporary discontinuation of oral anticoagulant therapies. Warfarin and other vitamin K antagonists directly suppress the synthesis of functional Protein C, leading to falsely low test results. Patients must stop taking warfarin for at least two weeks prior to the test, under the strict supervision of their prescribing physician. If anticoagulation cannot be safely paused, bridging therapy with low molecular weight heparin (LMWH) may be utilized, though even heparin must be discontinued at least 24 hours before sample collection.
• Timing Relative to Thrombotic Events: The Protein C test should not be performed during an acute thrombotic episode or within three months of a deep vein thrombosis or pulmonary embolism. Active clotting consumes coagulation factors and natural anticoagulants, which can lead to a transient, acquired deficiency and a false-positive diagnosis of inherited thrombophilia.
• Fasting Requirements: While strict fasting is not universally required for a standalone Protein C test, a fasting period of 8 to 12 hours is highly recommended if other lipid or metabolic profiles are being drawn concurrently. Patients are encouraged to remain well-hydrated by drinking plain water.
• Medical History Disclosure: Patients must inform the laboratory staff and their physician of all current medications, including oral contraceptives, hormone replacement therapy, and over-the-counter supplements, as well as any history of liver disease, recent surgeries, or active infections.

During the Procedure

The sample collection for a Protein C test is a standard venipuncture procedure executed with the highest clinical precision at Chughtai Lab. The process involves the following steps to ensure sample integrity:

• Patient Positioning and Identification: The patient is comfortably seated, and their identity is verified using double-identifiers in accordance with international patient safety standards.
• Site Selection and Preparation: A skilled phlebotomist inspects the antecubital fossa to select a suitable vein. The skin is thoroughly cleansed with an antiseptic solution and allowed to air dry completely to prevent hemolysis or contamination.
• Venipuncture and Sample Collection: A tourniquet is applied briefly. Prolonged tourniquet application (greater than one minute) is strictly avoided, as localized venous stasis can artificially elevate coagulation factors. The blood is drawn into a light blue-top tube containing 3.2% buffered sodium citrate. The precise 9:1 ratio of blood to anticoagulant is critical; underfilled or overfilled tubes cannot be processed as they yield inaccurate results.
• Post-Collection Handling: Immediately after drawing, the tube is gently inverted 3 to 4 times to ensure thorough mixing of the blood with the citrate anticoagulant. The sample is then promptly sent to the laboratory, where it undergoes rapid centrifugation to obtain platelet-poor plasma, which is then analyzed or frozen at ultra-low temperatures if testing is delayed.
• Patient Experience and Safety: The entire venipuncture process takes less than five minutes. Patients may feel a mild, brief pinch during needle insertion. After the needle is withdrawn, pressure is applied to the site, followed by the application of a sterile bandage to prevent hematoma formation.

When is a Protein C Test Performed?

Evaluating Unexplained Deep Vein Thrombosis (DVT)

Physicians frequently order a Protein C test when a patient presents with an unexplained or unprovoked deep vein thrombosis, particularly at a young age (under 50 years). Unprovoked DVT occurs without obvious risk factors such as major surgery, trauma, or prolonged immobility. Symptoms of DVT include unilateral leg swelling, warmth, erythema, and localized pain. Identifying a Protein C deficiency in these patients is crucial, as it helps determine the appropriate duration of anticoagulant therapy and guides long-term preventive strategies to mitigate the risk of recurrent thrombotic events.

Investigating Recurrent Pulmonary Embolism (PE)

Pulmonary embolism is a life-threatening condition that occurs when a blood clot detaches from a deep vein and travels to the lungs, obstructing the pulmonary arteries. Symptoms include sudden-onset dyspnea, pleuritic chest pain, tachypnea, tachycardia, and hemoptysis. When a patient experiences recurrent episodes of pulmonary embolism, or when a single episode occurs without a clear precipitating cause, a comprehensive thrombophilia workup, including a Protein C test, is indicated to identify underlying hypercoagulable states that require lifelong anticoagulation.

Assessing Family History of Inherited Thrombophilia

Inherited Protein C deficiency is a genetic disorder passed down in an autosomal dominant pattern. If a first-degree relative (parent, sibling, or child) has been diagnosed with a hereditary Protein C deficiency or has a history of severe, early-onset venous thromboembolism, clinical guidelines recommend screening asymptomatic family members. This proactive testing is especially important before these individuals undergo high-risk events, such as major orthopedic surgeries, pregnancy, or before starting estrogen-containing oral contraceptives, allowing clinicians to implement targeted prophylactic measures.

Diagnosing Neonatal Purpura Fulminans

In rare instances, a newborn may inherit defective Protein C genes from both parents, resulting in homozygous Protein C deficiency. This condition manifests shortly after birth as neonatal purpura fulminans, a catastrophic and rapidly progressive disorder characterized by widespread microvascular thrombosis, skin necrosis, and disseminated intravascular coagulation (DIC). Symptoms include rapidly expanding ecchymotic skin lesions, fever, and multi-organ failure. Immediate, emergency testing of Protein C levels is vital to confirm the diagnosis and initiate life-saving replacement therapy with Protein C concentrates or fresh frozen plasma.

Investigating Warfarin-Induced Skin Necrosis

Warfarin-induced skin necrosis is a rare but severe complication that occurs during the initiation of warfarin therapy, typically in patients with an underlying, unrecognized Protein C deficiency. When warfarin is started, it rapidly depletes Protein C (which has a very short half-life of about 6 hours) before depleting the procoagulant clotting factors II, IX, and X. This creates a transient, severe hypercoagulable state, leading to microvascular thrombosis in the skin and subcutaneous tissues, presenting as painful, dark skin lesions. A Protein C test helps confirm the underlying deficiency and guides alternative anticoagulation strategies.

What Does a Protein C Test Detect?

The Protein C test is highly sensitive to alterations in the coagulation cascade and can detect a wide range of congenital and acquired clinical conditions, including:

• Congenital Heterozygous Protein C Deficiency (Type I): Characterized by a quantitative decrease in both Protein C antigen levels and functional activity, leading to a lifelong increased risk of venous thrombosis.
• Congenital Heterozygous Protein C Deficiency (Type II): Characterized by a qualitative defect where the liver produces normal amounts of Protein C antigen, but the protein is dysfunctional, resulting in low functional activity.
• Homozygous Protein C Deficiency: A rare, life-threatening genetic state presenting in neonates with zero or near-zero Protein C activity, causing neonatal purpura fulminans.
• Vitamin K Deficiency: Since Protein C synthesis requires vitamin K, nutritional deficiencies or malabsorption syndromes lead to a significant decrease in functional Protein C levels.
• Acquired Deficiency due to Warfarin Therapy: Warfarin inhibits vitamin K epoxide reductase, resulting in the production of non-functional Protein C and a marked reduction in test values.
• Severe Liver Disease: Conditions such as cirrhosis, acute liver failure, or advanced hepatitis impair the synthetic capacity of the liver, leading to reduced production of Protein C.
• Disseminated Intravascular Coagulation (DIC): A systemic, pathological activation of coagulation that rapidly consumes clotting factors and natural anticoagulants, including Protein C.
• Active Acute Thrombosis: The acute phase of DVT or PE consumes circulating Protein C, resulting in temporarily depressed levels during the event.
• Severe Sepsis and Septic Shock: Inflammatory cytokines downregulate the endothelial expression of thrombomodulin and EPCR, while consuming Protein C, leading to acquired deficiency and microvascular thrombosis.
• Post-Operative Consumption: Major surgical procedures can trigger a transient hypercoagulable state and consumption of anticoagulant proteins in the immediate post-operative period.
• Malignancy-Associated Hypercoagulability: Certain cancers release procoagulant substances that consume natural anticoagulants, leading to mild to moderate acquired Protein C deficiency.
• Pregnancy-Induced Alterations: Normal pregnancy causes complex changes in the coagulation system, which can sometimes result in a mild, physiological decrease in Protein C activity.
• Oral Contraceptive and HRT Use: Estrogen-containing medications can slightly lower Protein C activity, contributing to the increased thrombotic risk associated with these therapies.
• Adult Respiratory Distress Syndrome (ARDS): Severe pulmonary inflammation can lead to localized consumption and degradation of Protein C within the pulmonary microvasculature.
• Nephrotic Syndrome: Severe renal disease characterized by heavy proteinuria can lead to the urinary loss of low-molecular-weight proteins, including Protein C.
• Severe Inflammatory Bowel Disease (IBD): Active flare-ups of Crohn’s disease or ulcerative colitis are associated with systemic inflammation that can depress Protein C levels.
• L-Asparaginase Chemotherapy: This chemotherapeutic agent, commonly used in leukemia treatment, inhibits hepatic protein synthesis, leading to a profound decrease in Protein C.
• Extracorporeal Membrane Oxygenation (ECMO): Continuous contact of blood with artificial biomaterials during ECMO therapy triggers coagulation activation and consumption of Protein C.
• Severe Thermal Burns: Extensive burn injuries cause massive systemic inflammation, capillary leak, and consumption of coagulation inhibitors.
• Catastrophic Antiphospholipid Syndrome (CAPS): An accelerated form of antiphospholipid syndrome resulting in widespread microvascular thrombosis and rapid depletion of Protein C.
• Severe Malnutrition: General protein-calorie malnutrition severely limits the amino acid substrates required for hepatic synthesis of coagulation proteins.
• Normal Anticoagulant Function: Normal Protein C levels rule out primary or secondary Protein C deficiency as the cause of a patient’s thrombotic symptoms.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its state-of-the-art laboratory infrastructure and highly optimized workflow, ensuring rapid turnaround times without compromising diagnostic accuracy. For specialized coagulation assays like the Protein C test, the turnaround time is typically within 24 to 48 hours from the time of sample collection. Because coagulation factors are highly sensitive to temperature and time, Chughtai Lab utilizes a strict cold-chain transport system to transfer samples from collection centers across Pakistan to the central reference laboratory in Lahore.

Once the analysis is complete, the results undergo a rigorous multi-level verification process by qualified medical technologists and consultant pathologists. Patients are immediately notified via SMS when their report is ready. Reports can be accessed and downloaded online through the official Chughtai Lab website or via the user-friendly Chughtai Lab Mobile App. Physical copies of the reports can also be collected from any Chughtai Lab diagnostic center or delivered directly to the patient’s home through their dedicated report delivery service.

Protein C Findings Overview

The interpretation of Protein C test results requires a comprehensive understanding of reference ranges and the patient’s clinical context. The table below outlines the typical parameters evaluated during a thrombophilia screen:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Protein C Activity (Functional)	70% – 140%	< 70% (Congenital or acquired deficiency, increased thrombotic risk); > 140% (Rare, clinically insignificant)
Protein C Antigen (Quantitative)	70% – 140%	< 70% (Type I deficiency, liver disease, vitamin K deficiency); Normal in Type II deficiency (dysfunctional protein)
Protein S Activity (Cofactor)	60% – 130%	< 60% (Protein S deficiency, pregnancy, oral contraceptive use, vitamin K deficiency)
Antithrombin III Activity	80% – 120%	< 80% (Antithrombin deficiency, heparin therapy, nephrotic syndrome, DIC)
Activated Protein C Resistance (APCR)	Ratio > 2.0 (Negative)	Ratio < 2.0 (Positive, highly suggestive of Factor V Leiden mutation)
Prothrombin Time (PT / INR)	INR 0.8 – 1.2	INR > 1.5 (Vitamin K deficiency, liver disease, warfarin therapy, consuming clotting factors)
Activated Partial Thromboplastin Time (aPTT)	25 – 35 seconds	Prolonged (Heparin therapy, lupus anticoagulant, intrinsic pathway factor deficiencies)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Protein C Test?

• Extensive National Network: Chughtai Lab operates a vast network of diagnostic centers and collection points across major cities in Pakistan, including Lahore, Karachi, and Islamabad, making high-quality testing highly accessible.
• Advanced Coagulation Platforms: The laboratory is equipped with fully automated, state-of-the-art coagulation analyzers that utilize precise optical and mechanical detection methods for highly accurate results.
• Expert Pathologist Supervision: All specialized hematology and coagulation tests are supervised, reviewed, and signed off by highly qualified consultant pathologists with extensive clinical experience.
• International Quality Standards: Chughtai Lab strictly adheres to international quality control guidelines, participating in external quality assurance programs (EQAS) to maintain the highest standards of diagnostic precision.
• Convenient Home Sample Collection: Patients can easily schedule a home sample collection through the Chughtai Lab website or mobile app, allowing professional phlebotomists to collect blood samples in the comfort of their homes.
• Seamless Digital Access: Patients can view, download, and share their diagnostic reports instantly via the official Chughtai Lab mobile application or online portal.
• 24/7 Customer Support: A dedicated customer care team is available around the clock to assist patients with test bookings, preparation guidelines, and report queries.
• Commitment to Patient Care: Chughtai Lab focuses on delivering compassionate, patient-centered care, ensuring a comfortable, safe, and hygienic environment at all diagnostic centers.